CervoMed (CRVO) Proxy filing summary

Executive summary

• The annual meeting will be held virtually on June 8, 2026, with shareholders able to vote online or by proxy on key proposals, including director elections, auditor ratification, executive compensation, and an amendment to the equity incentive plan.

• Eight directors are nominated for election, all of whom are current board members with diverse backgrounds in pharmaceuticals, finance, consulting, and investment.

• The board recommends voting in favor of all proposals, including the increase of shares available under the 2025 Equity Incentive Plan by 2,000,000 shares.

Voting matters and shareholder proposals

• Proposals include: election of eight directors, ratification of RSM US LLP as auditor for 2026, advisory approval of executive compensation, and approval of Amendment No. 1 to the 2025 Equity Incentive Plan.

• Shareholders may submit questions in advance or during the meeting, and can vote by internet, phone, mail, or virtually.

• The board unanimously recommends voting for all proposals.

Board of directors and corporate governance

• The board consists of eight members, six of whom are independent under Nasdaq and SEC rules.

• Leadership is separated between the Chair (Joshua S. Boger, PhD) and CEO (John Alam, MD) to enhance governance.

• Three standing committees: Audit, Compensation, and Nominating & Corporate Governance, each with independent directors.

• Directors are expected to attend at least 75% of meetings and annual meetings of stockholders.